Merck KGaA

News

Another mRNA company gets snapped up as Merck buys Exelead

The latest pharma company to make a move for an mRNA specialist is Germany's Merck KGaA, which has offered a $780 million cash buyout to US biotech Exelead.

News

GSK bails on $4.2bn partnership with Merck on cancer drug

GlaxoSmithKline has ended its collaboration with Germany's Merck KGaA's cancer treatment bintrafusp alfa, after a trio of failed clinical trials.

News

Third strike for GSK/Merck as bintrafusp alfa flubs again

GlaxoSmithKline's big gamble on Merck KGaA's bintrafusp alfa has gone from bad to worse, after the drug failed yet another mid-stage trial.

News

Scotland backs Bavencio for bladder cancer after NICE says n...

Patients with bladder cancer in Scotland will be the first in the UK to claim access to maintenance treatment with Merck Serono and Pfizer's Bavencio, ahead of their counterparts in England

News

Merck's targeted lung cancer drug tepotinib wins early acces...

The UK drugs regulator has backed Merck KGaA's MET inhibitor for the treatment of some patients with non-small cell lung cancer under the early access to medicines scheme (EAMS).

News

Merck makes another bioelectronics play, partnering with Inn...

Merck KGaA has forged a second partnership in the bioelectronics category in two weeks, teaming up with Innervia to develop neurostimulator devices for treating chronic diseases.

Another mRNA company gets snapped up as Merck buys Exelead

GSK bails on $4.2bn partnership with Merck on cancer drug

Third strike for GSK/Merck as bintrafusp alfa flubs again

Scotland backs Bavencio for bladder cancer after NICE says n...

Merck's targeted lung cancer drug tepotinib wins early acces...

Merck makes another bioelectronics play, partnering with Inn...

CDMOs: Their crucial role and how to select one, with Sigma ...

How to meet your physicians where they are online

Merck KGaA

Editor's Picks